ClinicalTrials.gg
RecruitingNCT06527222Updated Nov 18, 2026

A Study of Ranolazine in ALS

A Phase 2 interventional study of Ranolazine and Ranolazine in Amyotrophic Lateral Sclerosis, sponsored by Swathy Chandrashekhar, MBBS. Recruiting at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Swathy Chandrashekhar, MBBS · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Nov 18, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Planned enrollment
95th of 307
72 · median 33
Started
2025
with 26 others
Phase 2
89 of 440
8 open now
Primary completion
2028-07
later than 84 of 128 live
Registered
364th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 95th largest by planned enrollment of the 307 interventional ones that give a count, is one of 27 that started in 2025, is one of 89 in phase 2, reaches primary completion later than 84 of the 128 other live ones, and was the 364th registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate safety, effect on cramps, function and quality of life of ranolazine versus placebo for the treatment of ALS.

Read the detailed description

A prospective, multi center, double-blind, placebo-controlled, parallel group study of 2 doses of ranolazine (500 mg and 1000 mg twice daily) compared to placebo in patients with ALS.

Approximately 72 adults with ALS will be enrolled into the study in the United States at approximately 7 ALS treatment sites.

Participants will take oral ranolazine or placebo twice daily, attend a minimum of 5 onsite research visits, and 5 remote research visits.

The study is estimated to last 28 weeks for each participant.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • ALS
  • Motor Neuron Disease
  • Lou Gehrig's Disease
  • Placebo-Controlled
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Diagnosed with clinically definite, possible, probably, or lab-supported probable ALS per revised El Escorial criteria
  • Breathing assessment called forced vital capacity (FVC) greater than or equal to 50%.
  • Able to swallow pills at the start of the study and expected to for the length of the study.
  • If on ALS modifying medications must be on a stable dose at least 30 days.
  • Experiencing 4 or more cramps per week during a 2-week screening period.

Exclusion criteria

Exclusion Criteria:

  • Disease duration > 5 years
  • Tracheostomy invasive ventilation, or noninvasive ventilation of more than 12 hours/day
  • Pregnant or lactating, adults unable to consent, and prisoners
  • Taking ranolazine or drug or has received an investigational drug within 30 days (or 5 half-lives for drugs, whichever is longer) prior to screening
  • Medically uncontrolled comorbidities (heart, liver, kidney disease)
  • Baseline prolongation >450 ms for men/ >470 ms for women, history of long QT syndrome, or medications which prolong the QT interval
  • Participation in an experimental drug trial less than 30 days before screening
  • Patients have to be on a stable dosage of any medications used to treat muscle cramps for ≥30 days or have been off these medications ≥30 days prior to randomization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Ranolazine low dose

    Participants receive Ranolazine 500mg orally twice daily for 24 weeks.

    Drug: Ranolazine

  • Experimental
    Ranolazine high dose

    Participants receive Ranolazine 1000mg orally twice daily for 24 weeks.

    Drug: Ranolazine

  • Placebo comparator
    Placebo

    Participants receive Ranolazine placebo orally twice daily for 24 weeks.

    Drug: Placebo

Interventions

  • 500mg twice daily

    Also known as: Ranexa

  • 1000 mg twice daily

    Also known as: Ranexa

  • DrugPlacebo

    Ranolazine placebo twice daily

06

What researchers measure

Primary outcomes

  1. Frequency of Treatment-Emergent Adverse Events

    Patient report and medical records will be used to document adverse events and severe adverse events. Adverse events and severe adverse events will be assessed by the investigator and reported as needed for safety.

    Time frame: Up to 28 weeks

  2. Tolerability of treatment assignment

    Tolerability will be measured by percentage of patients who complete the treatment assignment. Dose limiting toxicities will be determined by individual with an adverse event necessitating stopping.

    Time frame: Up to 28 weeks

  3. Muscle cramp frequency

    Muscle cramp frequency will be measured numerically with a reporting period of 7 days. Changes will be compared from baseline to week 28 utilizing a modified Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity questionnaire.

    Time frame: Up to 28 weeks

  4. Muscle cramp severity

    Muscle cramp severity will be measured by a score of 1-10 (1 being a very mild muscle cramp and 10 being the most severe cramp you ever experienced). Changes will be compared from baseline to week 28 utilizing a modified Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity questionnaire.

    Time frame: Up to 28 weeks

  5. Muscle cramps impact on quality of life

    Effect of muscle cramps on quality of life will be measured with three patient reported yes or no questions (Yes indicating an impact on quality of life or no indicating no impact on quality of life). Changes will be compared from baseline to week 28 utilizing a modified Qualitative, Patient-Centered Assessment of Muscle Cramp Impact and Severity questionnaire

    Time frame: Up to 28 weeks

  6. Safety Lab Cystatin C

    Patient safety measured with lab value Cystatin C in mg/L.

    Time frame: Up to 28 weeks

  7. Safety Lab Estimated Glomerular Filtration Rate (eGFR)

    Patient safety measured with lab value eGFR in mL/min/1.73.

    Time frame: Up to 28 weeks

  8. Safety Lab Alanine Transaminase (ALT)

    Patient safety measured with lab value ALT in IU/L.

    Time frame: Up to 28 weeks

  9. Safety Lab Aspartate Transferase (AST)

    Patient safety measured with lab value AST in IU/L.

    Time frame: Up to 28 weeks

  10. Safety Lab Alkaline Phosphatase (ALP)

    Patient safety measured with lab value ALP in IU/L.

    Time frame: Up to 28 weeks

  11. Safety Lab Total Bilirubin

    Patient safety measured with lab value total bilirubin in mg/dL.

    Time frame: Up to 28 weeks

Secondary outcomes

  1. Muscle strength

    Change in muscle strength over time as measured by hand grip and hand-held dynamometry (HHD) in pounds.

    Time frame: Up to 28 weeks

  2. ALS Functional Rating Scale-Revised (ALSFRS-R)

    Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.

    Time frame: Up to 28 weeks

  3. Forced Vital Capacity (FVC)

    Change in respiratory function as measured by Forced Vital Capacity (FVC) in liters.

    Time frame: Up to 28 weeks

  4. Serum neurofilament light

    Changes in serum neurofilament light measured from baseline to end of treatment assignment. Data will be collected to determine differences between placebo and Ranolazine treatment groups at completion of the study.

    Time frame: Up to 28 weeks

  5. Lymphocyte Mitochondrial Function

    Change in mitochondrial function in lymphocytes measured from baseline to the end of treatment assignment. Data will be collected to determine differences between placebo and Ranolazine treatment groups at completion of the study

    Time frame: Up to 28 weeks

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jul 2028, 39 months after the start.

Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's planned 39 months is above that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2024
First posted
Jul 30, 2024
StartActual
Apr 29, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
1 exclusion criterion edited
What changed in the criteria
Exclusion criteria
  • EditedDisease duration <> 5 years
Nov 18, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • University of Kansas Medical Center: Wichita · Wichita, United StatesContact c•••@kumc.edu · •••1833→c•••@kumc.edu · •••1833Contact person changed (no phone or email listed)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • EditedDisease duration <> 5 years
    Site contacts Changed at 1 site. See the sites
    Show the site
    • University of Kansas Medical Center: Wichita · Wichita, United StatesContact c•••@kumc.edu · •••1833→c•••@kumc.edu · •••1833Contact person changed (no phone or email listed)
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06527222
Lead sponsor
Swathy Chandrashekhar, MBBS
Collaborators
ALS Association
Responsible party
Swathy Chandrashekhar, MBBS (Principal Investigator, University of California, San Francisco) — Sponsor-investigator
First posted
Jul 30, 2024
Start date
Apr 29, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Katie Lillig, BS
Contact
Kjennens2@kumc.edu
913-945-9932
Jeffrey Statland, MD
principal investigator · University of Kansas Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranolazine

Start the discussion